Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

NICE Appraisal Changes: Confusing, Contradictory & Questionable

Executive Summary

New NICE and NHS England appraisal rules regarding timelines and price thresholds could fast-track new cost-effective drugs but then delay them from reaching patients for up to three years. The new regulations, which will come into force in April, have raised a lot of questions around methodology and impact outside of England.

Advertisement

Related Content

UK Pharma’s Bid To Curb NHS Pricing Power Fails In Court
UK BioPharma Players Told 'Think Global, Act Local' For Post-Brexit World

Topics

Advertisement
UsernamePublicRestriction

Register

PS120240

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel